Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
AGOURA HILLS, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (Oncotelic or the Company) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including Parkinson Disease and various cancers, today announced the Company will be presenting at the BIO International Convention taking place in San Diego, California between June 13 - 16, 2022.
Dr. Vuong Trieu, CEO and Chairman, will be presenting an overview of the Oncotelics pipeline, including update on Sapu Therapeutics, LLC, one of our subsidiaries in the joint venture between Dragon Overseas Capital Ltd. (Dragon) and GMP Biotechnology, LLC. (GMP Bio).
To learn more about the BIO International Convention or register to attend, visit the conference website at https://www.bio.org/events/bio-international-convention. To attend Dr. Trieus session, please check our website for the presentation time closer to the date of the conference.
About Dr. Trieu
Dr. Vuong Trieu was the founder and Chairman of the Board of Directors of Oncotelic Inc., having served in such capacity since 2014, and now serves as the Companys Chief Executive Officer (the "CEO) and Chairman of the Board of Directors. Dr. Trieu has been involved in drug discovery, development, and commercialization for over 25 years, including his contributions as co-inventor of Abraxane. He previously served as Executive Chairman and Interim CEO of Marina Biotech, Inc. from 2016 to 2018. Marina Biotech was a developer of tkRNA for the treatment of FAP/CRC (Familial adenomatous polyposis/ Colorectal Cancer). Prior to that, he also served as President and CEO of IgDraSol, Inc. - a developer of a 2nd generation Abraxane, beginning in 2012 until its acquisition by Sorrento Therapeutics, Inc. (Sorrento) in 2013. He served as Chief Scientific Officer for Sorrento Therapeutics, Inc. and was also a member of Sorrentos board of directors from 2013 until 2014. Previously, Dr. Trieu was Senior Director of Pharmacology/Biology at Abraxis Bioscience/Celgene, where he led the preclinical, clinical and PK/biomarker development of Abraxane, and was the co-inventor of the intellectual property covering Abraxane. Earlier in his career, Dr. Trieu held positions at Genetic Therapy/Sandoz (leading the adenoviral gene therapy program against atherosclerosis), Applied Molecular Evolution (AME)/Lily (leading the expression, purification, and preclinical testing of mAb therapeutics) and Parker Hughes Institute (Director of Cardiovascular Biology program that evaluated a series of small molecules and biologics against preclinical models of atherosclerosis, dyslipidemia, stroke, ALS, and restenosis). Dr. Trieu holds a PhD in Microbiology, BS in Microbiology and Botany. He is a member of ENDO, ASCO, AACR, and many other professional organizations. Dr. Trieu is published widely in oncology, cardiovascular, and drug development.
Dr. Trieu has over 100 patent applications and 39 issued U.S. patents.
About Oncotelic
Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for DIPG (OT-101) through its 45% joint venture, melanoma (CA4P), and AML (OXi 4503). Oncotelic also acquired PointR Data Inc. in November 2019.
Oncotelic acquired AL-101, during the 4th quarter of 2021, for the intranasal delivery of apomorphine. We intend to develop AL-101 for the treatment of Parkinson Disease (PD). Over 60,000 new patients are being diagnosed with PD in the United States and currently there are over 1 million patients in the US and expected to increase to over 1.2 million by 2030. In addition, approximately10millionsufferfromthisdiseaseglobally.https://www.parkinson.org/Understanding-Parkinsons/Statistics. AL-101 is also being developed for Erectile Dysfunction (ED). ED is the most prevalent male sexual disorder globally. The percentages of men affected by ED are as follows: 14.3-70% of men aged 60 years, 6.7-48% of men aged 70 years, and 38% of men aged 80 years (Geerkens MJM et al. (2019). Eur Urol Focus. pii: S2405-4569(19)30079-3). However, with the increasing administration of PDE5 inhibitors in clinical practice, it was found that approximately 30-35% of ED patients are treatment failures (McMahon CN et al. (2006). BMJ, 332: 589-92). AL-101 is designed to target treatment failure ED patients who do not respond to PDE5 inhibitors. Through similar mechanism of action, AL-101 is being developed for Female Sexual Dysfunction (FSD). Female sexual dysfunction is a prevalent problem, afflicting approximately 40% of women and there are few treatment options. FSD is more typical as women age and is a progressive and widespread condition. (Allahdadi, KJ et al. (2009) Cardiovascular & hematological agents in medicinal chemistry, 7(4), 260269). There is no available drug for the treatment of FSD. In June 2019, the U.S. Food and Drug Administration approved Vyleesi (bremelanotide) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. This is the only available drug treatment. Vyleesi has essentially replaced the only other drug for HSDD however, it has a long list of drug-drug interactions, including commonly used antidepressants, such as fluoxetine and sertraline. In addition, it has a black box warning regarding its use with alcohol, a combination that has been associated with hypotension and syncopal episodes. Therefore, there is an urgent need for effective therapy against FSD and HSDD.
About OT-101
Oncotelic jointly owns OT-101 with its joint venture partners Dragon and GMP Bio. OT-101 has completed seven clinical trials including one phase 2 trial in COVID and two phase 2 trials in brain cancer and against pancreatic cancer. It has pediatric designation for a rare form of pediatric brain cancer known as DIPG. There are about 200-300 new cases of DIPG every year in the United States. DIPG most often occurs in children aged 5-10 years old. Treatment options are limited with surgery being contraindicated. Most children do not survive more than 2 years after diagnosis. Currently, the main treatment for DIPG is radiation therapy. Although radiation temporarily improves symptoms in most patients, it is not a cure. Palliative care or quality of life services help patients and families manage pain and other symptoms, promote quality of life, and making difficult decisions including treatment choices and end of life care.
When COVID-19 emerged in China, Oncotelic and GMP entered into a research and services agreement in February 2020 to develop and test COVID-19 antisense therapeutics. In March 2020, Oncotelic reported the anti-viral activity of OT-101. The anti-viral activity of OT-101, in an in vitro antiviral testing performed by an independent laboratory, OT-101 has a 50% effective concentration (EC50) of 7.6 g/mL and is not toxic at the highest dose of 1000 g/mL giving a safety index (SI) value of >130, which is considered highly active and on par or superior to Remdesivir - a Gilead drug. Unlike Remdesivir, OT-101 targets not only the virus replication but also the virus induced pneumonia and fibrosis. Our Phase 2 trial was completed for OT-101 in South America. This was a randomized, double-blind, placebo-controlled Phase 2 study intended to evaluate the safety and efficacy of OT-101 in adult patients hospitalized with positive SARS-CoV-2 and pneumonia. As reported in November 2021, the top line data was positive for safety and efficacy.
For more information, please visit http://www.oncotelic.com
Oncotelic's Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the company's product candidates and the potential use of the company's product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, taking the Company or its affiliates through initial public offerings. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's annual report on Form 10-K filed with the SEC on April 15, 2022 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether as a result of new information future events, or otherwise.
Contact Information:
For Oncotelic Therapeutics, Inc.:
Amit Shah
[emailprotected]
See the original post here:
Oncotelic Announces Pipeline Presentation and IPO Update of Sapu Therapeutics at the 2022 BIO International Convention - StreetInsider.com
- Cardiology and Cardiac Pharmacology - April 4th, 2018 [April 4th, 2018]
- EMS Pharmacology: Drugs That Affect the Cardiovascular System ... - April 8th, 2018 [April 8th, 2018]
- EMS Pharmacology: Drugs That Affect the Cardiovascular ... - April 11th, 2018 [April 11th, 2018]
- Cardiology Conferences - Cardiology and Cardiovascular ... - June 5th, 2018 [June 5th, 2018]
- Cardiovascular Pharmacology: Open Access - Open Access ... - June 21st, 2018 [June 21st, 2018]
- CV Pharmacology | Welcome to Cardiovascular Pharmacology ... - July 31st, 2018 [July 31st, 2018]
- Cardiology Conferences | Cardiac pharmacology 2018 ... - September 13th, 2018 [September 13th, 2018]
- Cardiology Conference | Cardiac Pharmacology 2019 ... - November 18th, 2018 [November 18th, 2018]
- Cardiovascular Pharmacology Online Course | Lecturio - November 30th, 2018 [November 30th, 2018]
- Cardiovascular Pharmacology: Open Access - December 16th, 2018 [December 16th, 2018]
- Cardiovascular In vivo Models for Drug Discovery - December 21st, 2018 [December 21st, 2018]
- UTHSC College of Medicine: Department of Pharmacology - February 2nd, 2019 [February 2nd, 2019]
- Department of Pharmacology - School of Medicine - LSU ... - April 5th, 2019 [April 5th, 2019]
- Cardiovascular Pharmacology: Open Access - longdom.org - April 22nd, 2019 [April 22nd, 2019]
- ASPET | Cardiovascular Pharmacology - September 14th, 2019 [September 14th, 2019]
- Pharmacogenomics Market (PGx) Competitive Research And Precise Outlook 2019 To 2025: Astrazeneca, GeneDX, Illumina, Inc., Laboratory Corporation of... - September 18th, 2019 [September 18th, 2019]
- Global and Chinese Microbiome Drugs Market: Industry strategic plan for the period 2019-2024 - Market Report Gazette - September 18th, 2019 [September 18th, 2019]
- Pharmacokinetics Market To Increase at Steady Growth Rate - Commerce Gazette - September 18th, 2019 [September 18th, 2019]
- Moderna Announces Positive Phase 1 Results for the First Systemic Messenger RNA Therapeutic Encoding a Secreted Protein (mRNA-1944) - BioSpace - September 18th, 2019 [September 18th, 2019]
- Janssen to Highlight Depth of Prostate Cancer and Solid Tumor Portfolios with Multiple Data Presentations at ESMO 2019 - Yahoo Finance - September 18th, 2019 [September 18th, 2019]
- Cardiac fibrosis study identifies key proteins that translate into heart disease - BSA bureau - September 18th, 2019 [September 18th, 2019]
- Nitric Oxide: Worldwide Therapeutics & Markets to 2028 with Profiles on 35 Companies & 18 Collaborations Tabulated - Yahoo Finance - September 18th, 2019 [September 18th, 2019]
- Cytokinetics Announces Data From Phase 1 Study of CK-3773274 at the HFSA 23 Annual Scientific Meeting - Yahoo Finance - September 18th, 2019 [September 18th, 2019]
- Is it risky to continue with blood thinner drugs after a gastrointestinal bleed? - Medical News Bulletin - September 18th, 2019 [September 18th, 2019]
- Women urged to exercise and eat well due to cholesterol after menopause - Sydney Morning Herald - September 18th, 2019 [September 18th, 2019]
- Former Executive Director of Preclinical Safety at Novartis, Klaus Peter Hoffmann, MD, PhD, Joins NDA Partners as Expert - Yahoo Finance - September 18th, 2019 [September 18th, 2019]
- Yale alumna Dr. Nancy Brown named dean of Yale School of Medicine - Yale News - September 18th, 2019 [September 18th, 2019]
- Verve Therapeutics Appoints Cardiologist Andrew Bellinger, M.D., Ph.D., as Chief Scientific Officer - Business Wire - October 7th, 2019 [October 7th, 2019]
- G-Protein Coupled Receptors (GPCRs) Market Size And Prediction By Leading Manufacturers According To Its Application And Types Till 2022 - Space... - October 7th, 2019 [October 7th, 2019]
- Best supplements for blood pressure: The natural remedy proven to lower your reading - Express - October 7th, 2019 [October 7th, 2019]
- Advanced Drug Delivery Systems Market Growth Analysis 2019 to Share Key Aspects of the Industry with the details of Influence Factors Forecast to 2024... - October 28th, 2019 [October 28th, 2019]
- The 9 Biggest Technology Trends That Will Transform Medicine And Healthcare In 2020 - Forbes - November 6th, 2019 [November 6th, 2019]
- Potential PF Therapy AD-214 to Move into Phase 1 Testing in Humans - Pulmonary Fibrosis News - November 6th, 2019 [November 6th, 2019]
- Edited Transcript of CYTK earnings conference call or presentation 31-Oct-19 8:30pm GMT - Yahoo Finance - November 6th, 2019 [November 6th, 2019]
- The Montreal Heart Institute celebrates its 500th heart transplant - GlobeNewswire - November 6th, 2019 [November 6th, 2019]
- Latest Research Report to uncover key Factors of Global Cardiovascular Repair And Reconstruction Devices Market - Market Research Base - November 6th, 2019 [November 6th, 2019]
- Global Cardiovascular Repair And Reconstruction Devices Market: Development History, Current Analysis and Estimated Forecast to 2025 - Market Research... - November 29th, 2019 [November 29th, 2019]
- The cardiac safety services market is projected to reach USD 752 million by 2024 from USD 442 million in 2019, at a CAGR of 11.2% - Yahoo Finance - December 11th, 2019 [December 11th, 2019]
- Evaluation of the Effect of Fish Oil Alone and in Combination with a P | DMSO - Dove Medical Press - January 13th, 2020 [January 13th, 2020]
- Amarin's Multiple Positives And Other News: The Good, Bad, And Ugly Of Biopharma - Seeking Alpha - January 25th, 2020 [January 25th, 2020]
- Heres What We Know About CBDs Effects On Varicose Veins - The Fresh Toast - January 28th, 2020 [January 28th, 2020]
- Hypertension: This Spice Can Help You Control High Blood Pressure Easily And Effectively - Doctor NDTV - January 28th, 2020 [January 28th, 2020]
- Cannabis Manual: Better Together - Weekly Alibi - January 30th, 2020 [January 30th, 2020]
- Pharmacology: Cardiovascular Drugs 1 (30 Items) - Nurseslabs - March 1st, 2020 [March 1st, 2020]
- A central master driver of psychosocial stress responses in the rat - Science Magazine - March 9th, 2020 [March 9th, 2020]
- The Global Cardiac Safety Services Market is expected to grow from USD 419.45 Million in 2018 to USD 865.23 Million by the end of 2025 at a Compound... - March 29th, 2020 [March 29th, 2020]
- Milestone Pharmaceuticals Announces Topline Results from First-of-its-kind Phase 3 NODE-301 Trial of Etripamil for At-home Acute PSVT Treatment -... - March 29th, 2020 [March 29th, 2020]
- Fresh Produce In Short Supply? Prioritize This Veggie In Your Diet - mindbodygreen.com - April 25th, 2020 [April 25th, 2020]
- COVID-19: What's RNA research got to do with it? - University of Rochester - May 1st, 2020 [May 1st, 2020]
- What Happens When You Add Other Drugs To Your LSD Trip? - VICE - May 1st, 2020 [May 1st, 2020]
- Toward a Pharmacology of Resolution - Harvard Magazine - May 1st, 2020 [May 1st, 2020]
- GLYCOMIMETICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) - marketscreener.com - May 2nd, 2020 [May 2nd, 2020]
- This Simple Breathing Advice From A Nobel Prize Winner Can Turn The Tables On Stress During The Coronavirus Lockdown - Forbes - May 2nd, 2020 [May 2nd, 2020]
- National Nurses Week 2020: What Experiences Have Shaped Your Nursing Career? - HealthLeaders Media - May 2nd, 2020 [May 2nd, 2020]
- Research Paper Stresses Importance of Repurposing Drugs Against COVID-19 - BioSpace - May 13th, 2020 [May 13th, 2020]
- Repurposing existing drugs to treat coronavirus will likely be quicker than a vaccine, scientists claim - CNBC - May 13th, 2020 [May 13th, 2020]
- Alzheimer's and Cannabis - Greenway - Greenway - May 18th, 2020 [May 18th, 2020]
- Moderna Highlights Advances in Platform Science and Innovative Vaccine Research at Third Annual Science Day - Business Wire - June 2nd, 2020 [June 2nd, 2020]
- Healthy people shouldn't take daily aspirin to prevent heart disease, review finds - WDJT - June 6th, 2020 [June 6th, 2020]
- Study reveals how living close to roadways may impact the brain - Drew Reports News - June 18th, 2020 [June 18th, 2020]
- Disruptions in circadian rhythms not only cause sleep disorders, but could also put you at risk of these... - Firstpost - June 18th, 2020 [June 18th, 2020]
- NeonMind Files Patent Application for Therapeutic Use of DMT - Yahoo Finance - June 18th, 2020 [June 18th, 2020]
- Vitamin D What you need to know about the sunshine vitamin - Medical News Bulletin - July 9th, 2020 [July 9th, 2020]
- Idorsia announces positive results in the second Phase 3 study of daridorexant - GlobeNewswire - July 9th, 2020 [July 9th, 2020]
- ATAI Life Sciences takes on opioid crisis by acquiring Kures to develop novel therapeutics for opioid abuse - PRNewswire - July 9th, 2020 [July 9th, 2020]
- Drug Discovery Outsourcing Market Highly Favorable with new Demand to the Growth Rate by 2027| Thermo Fisher Scientific, Merck KGaA, Albany Molecular... - August 21st, 2020 [August 21st, 2020]
- Bringing Peer Review To Early COVID-19 Research, More News - Bio-IT World - August 21st, 2020 [August 21st, 2020]
- Cardiac Safety Services Market Research Report by Type of Service, by Type, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19 -... - August 21st, 2020 [August 21st, 2020]
- UCI study finds women with diabetes and high levels of coronary artery calcium at greater risk of death than men - Newswise - August 21st, 2020 [August 21st, 2020]
- Globa Advanced Drug Delivery Systems Market 2020 Research, Key Players, Industry Overview, Supply and Consumption Analysis 2024 - Bulletin Line - September 2nd, 2020 [September 2nd, 2020]
- Esperion Announces Two Data Presentations of NEXLETOL (bempedoic acid) Tablet at the ESC Congress 2020 - GlobeNewswire - September 2nd, 2020 [September 2nd, 2020]
- Women with diabetes and high levels of coronary artery calcium at greater risk of death than men - UCI News - September 2nd, 2020 [September 2nd, 2020]
- 15 Clever Ways to Use Leftover Red Wine - Yahoo Lifestyle - September 2nd, 2020 [September 2nd, 2020]
- UK Study Leads to Better Understanding of Blood Pressure Regulation, Atherosclerosis - UKNow - September 2nd, 2020 [September 2nd, 2020]
- Academic always top of the class for pay and conditions - Extra.ie - September 15th, 2020 [September 15th, 2020]
- Cardiac Safety Services Market Size Is Rising Tremendously Due To Increasing Need of Healthcare Services Centralization Till 2025 - TC BizNews - September 15th, 2020 [September 15th, 2020]
- 5 Benefits of Berberine, Including Why It's a Healthy Gut All-Star - msnNOW - September 15th, 2020 [September 15th, 2020]
- Advanced Drug Delivery Systems Market 2020 Report Covers Key Growth Factors, Global Trends, Opportunities by Regions, Industry Size and Share... - September 23rd, 2020 [September 23rd, 2020]
- Janssen Presents Findings from Global, Multi-Center Trial Examining Amivantamab in Combination with Lazertinib in Patients with EGFR-Mutated Non-Small... - September 23rd, 2020 [September 23rd, 2020]
- MASSIVE GROWTH OF DRUG DISCOVERY SERVICES MARKET WILL RAISE USD 19.1 BILLION BY 2027, CAGR +13% FROM 2020 TO 2027 WITH TOP KEY PLAYERS LIKE THERMO... - September 29th, 2020 [September 29th, 2020]